Your browser is no longer supported. Please, upgrade your browser.
Settings
BLPH Bellerophon Therapeutics, Inc. daily Stock Chart
BLPH [NASD]
Bellerophon Therapeutics, Inc.
Index- P/E47.69 EPS (ttm)0.01 Insider Own6.00% Shs Outstand67.90M Perf Week-3.43%
Market Cap42.10M Forward P/E- EPS next Y-0.40 Insider Trans98.48% Shs Float43.00M Perf Month-4.62%
Income2.80M PEG- EPS next Q- Inst Own47.60% Short Float1.46% Perf Quarter-6.06%
Sales- P/S- EPS this Y103.10% Inst Trans-0.06% Short Ratio1.98 Perf Half Y-34.05%
Book/sh0.07 P/B8.86 EPS next Y20.40% ROA10.50% Target Price3.00 Perf Year-72.20%
Cash/sh0.24 P/C2.54 EPS next 5Y- ROE505.90% 52W Range0.47 - 3.30 Perf YTD-22.64%
Dividend- P/FCF- EPS past 5Y15.00% ROI- 52W High-81.21% Beta-0.02
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low31.91% ATR0.04
Employees17 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)42.19 Volatility5.16% 6.67%
OptionableNo Debt/Eq0.00 EPS Q/Q96.40% Profit Margin- Rel Volume0.29 Prev Close0.63
ShortableYes LT Debt/Eq0.00 EarningsMar 21 BMO Payout0.00% Avg Volume316.57K Price0.62
Recom2.00 SMA20-5.50% SMA50-6.61% SMA200-39.99% Volume92,876 Change-1.01%
Jan-24-19Initiated Maxim Group Buy $3
Apr-17-17Initiated Ladenburg Thalmann Buy $4.50
Jan-20-17Initiated H.C. Wainwright Buy $5
Mar-22-16Reiterated Leerink Partners Outperform $11 → $9
Jul-27-15Reiterated FBR Capital Outperform $23 → $11
Mar-16-15Initiated FBR Capital Outperform $23
Apr-08-19 08:30AM  Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +7.53%
Mar-18-19 02:08PM  Did Changing Sentiment Drive Bellerophon Therapeuticss (NASDAQ:BLPH) Share Price Down A Painful 76%? Simply Wall St.
Mar-14-19 09:09AM  Bellerophon Therapeutics: 4Q Earnings Snapshot Associated Press
08:30AM  Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Jan-28-19 08:30AM  Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients GlobeNewswire
Jan-25-19 04:05PM  Bellerophon Announces Closing of $7 Million Public Offering of Common Stock GlobeNewswire
Jan-23-19 06:00AM  Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock GlobeNewswire -23.91%
Jan-22-19 04:44PM  Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -7.57%
Jan-07-19 08:30AM  Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +26.74%
Nov-21-18 08:55AM  Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-16-18 01:32AM  DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire
Nov-07-18 09:36AM  Bellerophon Therapeutics: 3Q Earnings Snapshot Associated Press +8.33%
08:30AM  Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-09-18 08:30AM  Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Sep-10-18 11:40AM  3 Biotech & Marijuana Stocks to Pay Attention to this Quarter ACCESSWIRE +28.18%
Aug-29-18 08:00AM  Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 08:00AM  Todays Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics ACCESSWIRE +10.75%
Aug-08-18 08:15AM  The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga -15.34%
Aug-07-18 08:30AM  Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire -68.86%
Aug-01-18 09:16AM  Bellerophon Therapeutics: 2Q Earnings Snapshot Associated Press
08:40AM  Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jun-15-18 09:13AM  5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks
Jun-12-18 08:39AM  The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp Zacks -6.00%
08:00AM  Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference GlobeNewswire
Jun-11-18 12:45PM  5 Top-Ranked Small Caps to Buy as Trade Tensions Escalate InvestorPlace
09:08AM  Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate Zacks
May-16-18 08:30AM  Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference GlobeNewswire
May-10-18 08:45AM  Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 08:30AM  Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire
Apr-30-18 08:43AM  Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher Zacks
Apr-19-18 09:35AM  3 Biotech Stocks That Will Thrive Amid Market Instability InvestorPlace +5.31%
Apr-03-18 08:30AM  Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-27-18 07:00AM  Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018 ACCESSWIRE
Mar-23-18 10:56AM  Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher? Zacks -8.39%
Mar-15-18 07:17PM  Bellerophon Therapeutics posts 4Q loss Associated Press
04:45PM  Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Jan-29-18 08:30AM  Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire
Jan-03-18 08:30AM  Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-30-17 05:46PM  Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors GlobeNewswire
Nov-07-17 08:43AM  Bellerophon Therapeutics posts 3Q loss Associated Press
08:30AM  Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Sep-27-17 08:30AM  Bellerophon Announces $23 Million Private Placement GlobeNewswire +18.52%
Sep-07-17 04:01PM  Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences GlobeNewswire
Sep-05-17 08:40AM  Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment MarketWatch
08:30AM  Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire
Aug-07-17 11:57PM  Bellerophon Therapeutics posts 2Q loss Associated Press
08:00AM  Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-03-17 08:30AM  Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) GlobeNewswire
May-22-17 04:01PM  Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference GlobeNewswire
May-16-17 08:00AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics Accesswire
May-15-17 08:22AM  Bellerophon Therapeutics posts 1Q loss Associated Press -5.10%
08:00AM  Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
May-10-17 08:00AM  Bellerophon Announces $3.0 Million Registered Direct Offering GlobeNewswire
May-01-17 08:01AM  Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference GlobeNewswire
Apr-07-17 11:05AM  Bellerophon Slumps on Underwhelming INOpulse Data Investopedia
07:00AM  Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) GlobeNewswire
Mar-27-17 08:00AM  Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation GlobeNewswire
Mar-21-17 09:30AM  The Difference Between Spectacular News and No News Accesswire
Mar-16-17 01:04PM  BELLEROPHON THERAPEUTICS, INC. Financials
06:15AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Mar-13-17 08:47AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
07:52AM  Bellerophon Therapeutics posts 4Q loss Associated Press
07:30AM  Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
06:20AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Feb-23-17 08:10AM  LifeSci Capital Initiates Coverage of Bellerophon Therapeutics Accesswire
Jan-20-17 07:15AM  Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright
Jan-06-17 05:18PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Jan-04-17 08:38AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program GlobeNewswire
Dec-22-16 01:10PM  These 5 Stocks Under $10 Could Make You a Lot of Money TheStreet.com
01:10PM  These 5 Stocks Under $10 Could Make You a Lot of Money
Dec-12-16 05:26PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-29-16 05:11PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
Nov-23-16 06:30AM  Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering GlobeNewswire
Nov-15-16 05:09PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
Nov-09-16 10:21AM  Bellerophon Therapeutics posts 3Q loss
Nov-08-16 07:08AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
07:03AM  Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
06:40AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-01-16 02:09PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
12:50PM  Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders Business Wire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH) PR Newswire
Oct-31-16 08:00AM  Second Law Firm Hits Bellerophon (BLPH) at Investopedia
Oct-28-16 12:19PM  INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith Business Wire
Oct-26-16 01:29PM  Law Firm Targets Bellerophon Therapeutics (BLPH) at Investopedia
09:02AM  Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp. PR Newswire
Sep-20-16 06:54AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
06:33AM  Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016 GlobeNewswire
Sep-06-16 06:37AM  Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-09-16 07:02AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
06:41AM  Bellerophon Therapeutics posts 2Q loss
06:33AM  Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Jul-27-16 07:54AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jul-25-16 12:05PM  Bellerophon Gets Approval To Start Second Stage Study In PH-COPD
06:03AM  Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD GlobeNewswire
Jun-17-16 04:53PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-16-16 06:44AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:03AM  Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH) GlobeNewswire
May-27-16 04:34PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
May-13-16 07:49AM  6 Stocks Under $10 Making Big Moves Higher at TheStreet
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peacock Jonathan MDirectorJan 25Buy0.70714,286500,0001,855,920Jan 25 04:21 PM
Wang Theodore TDirectorJan 25Buy0.70450,000315,000463,699Jan 25 04:22 PM
Amin NaseemDirectorJan 25Buy0.70571,429400,0001,818,867Jan 25 04:12 PM
VENROCK ASSOCIATES IV L P10% OwnerJan 23Buy0.70142,857100,0007,529,020Mar 14 05:57 PM
VENROCK ASSOCIATES IV L P10% OwnerJan 23Buy0.70142,857100,0007,529,020Mar 14 05:51 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 17Buy1.1860,00070,9447,386,163Sep 17 04:46 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 17Buy1.1860,00070,9447,386,163Sep 17 04:42 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 14Buy1.2375,00092,2507,326,163Sep 17 04:42 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 14Buy1.2375,00092,2507,326,163Sep 17 04:46 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 13Buy1.1975,00089,1607,251,163Sep 17 04:46 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 13Buy1.1975,00089,1607,251,163Sep 17 04:42 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 12Buy1.1575,00085,9137,176,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 12Buy1.1575,00085,9137,176,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 11Buy1.14200,000228,8407,101,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 11Buy1.14200,000228,8407,101,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 10Buy1.22200,000243,6406,901,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 10Buy1.22200,000243,6406,901,163Sep 12 09:00 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 07Buy0.9060,00053,7426,701,163Sep 07 05:45 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 07Buy0.9060,00053,7426,701,163Sep 07 05:42 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 06Buy0.8450,00042,0956,641,163Sep 07 05:42 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 06Buy0.8450,00042,0956,641,163Sep 07 05:45 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 05Buy0.8550,00042,3256,591,163Sep 07 05:45 PM
VENROCK ASSOCIATES IV L P10% OwnerSep 05Buy0.8550,00042,3256,591,163Sep 07 05:42 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 16Buy0.6566,39343,1096,541,163Aug 16 07:31 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 16Buy0.6566,39343,1096,541,163Aug 16 07:33 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 15Buy0.65272,000175,9026,474,770Aug 16 07:33 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 15Buy0.65272,000175,9026,474,770Aug 16 07:31 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 14Buy0.65190,977123,8686,202,770Aug 16 07:31 PM
VENROCK ASSOCIATES IV L P10% OwnerAug 14Buy0.65190,977123,8686,202,770Aug 16 07:33 PM